Wedbush Reiterates “Outperform” Rating for Telix Pharmaceuticals (NASDAQ:TLX)

Telix Pharmaceuticals (NASDAQ:TLX)‘s stock had its “outperform” rating restated by analysts at Wedbush in a note issued to investors on Wednesday, Benzinga reports. They presently have a $22.00 price target on the stock. Wedbush’s price target points to a potential upside of 96.50% from the company’s previous close.

A number of other analysts also recently commented on TLX. Citigroup reiterated a “buy” rating on shares of Telix Pharmaceuticals in a report on Thursday, August 20th. Weiss Ratings upgraded Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, August 21st. Royal Bank Of Canada upgraded Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research report on Monday. Finally, HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Telix Pharmaceuticals in a research note on Tuesday, September 15th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, Telix Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $20.50.

Telix Pharmaceuticals Price Performance

NASDAQ:TLX traded down $0.07 during mid-day trading on Wednesday, reaching $11.20. 446,334 shares of the stock were exchanged, compared to its average volume of 218,613. The company has a debt-to-equity ratio of 1.16, a current ratio of 2.01 and a quick ratio of 1.85. The business has a fifty day moving average price of $11.32 and a 200 day moving average price of $10.44. Telix Pharmaceuticals has a 1-year low of $6.28 and a 1-year high of $13.11.

Institutional Investors Weigh In On Telix Pharmaceuticals

Several hedge funds have recently bought and sold shares of TLX. Lazard Asset Management LLC grew its holdings in shares of Telix Pharmaceuticals by 15.7% during the 1st quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock valued at $2,775,000 after acquiring an additional 39,400 shares in the last quarter. Hennion & Walsh Asset Management Inc. bought a new stake in Telix Pharmaceuticals in the second quarter worth approximately $1,731,000. Private Advisor Group LLC raised its holdings in shares of Telix Pharmaceuticals by 276.3% during the 1st quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock valued at $1,669,000 after purchasing an additional 128,070 shares in the last quarter. XY Capital Ltd raised its holdings in shares of Telix Pharmaceuticals by 468.0% during the 2nd quarter. XY Capital Ltd now owns 71,291 shares of the company’s stock valued at $822,000 after purchasing an additional 58,739 shares in the last quarter. Finally, Bank of America Corp DE raised its holdings in shares of Telix Pharmaceuticals by 523.8% during the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock valued at $96,000 after purchasing an additional 8,423 shares in the last quarter.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products use targeted molecules to deliver radioactive isotopes to specific tissues, supporting precision imaging and therapeutic applications.

The company’s commercial portfolio includes Illuccix, a gallium-68 radiolabeled prostate-specific membrane antigen (PSMA) imaging agent used with PET scans to help detect and manage prostate cancer.